Portrait of Glenn Rosenbluth
  • Telehealth visits
bch logo

Glenn Rosenbluth, MD

Pediatric Hospital MedicineMedical Director, Craniofacial Center
Pediatric Craniofacial Mission Bay
877-822-4453
Portrait of Glenn Rosenbluth
Portrait of Glenn Rosenbluth
bch logo

Glenn Rosenbluth, MD

Pediatric Hospital MedicineMedical Director, Craniofacial Center
Pediatric Craniofacial Mission Bay
877-822-4453

On this page

About me

Dr. Glenn Rosenbluth is a pediatric hospitalist, a specialist in coordinating and managing the care of hospitalized children, who are often being treated by many specialists. His special interests include caring for children with medically complex conditions, improving patient safety and other issues related to quality improvement, and medical education.

Rosenbluth earned his medical degree at Weill Cornell Medicine and completed a residency in pediatrics, serving as chief resident, at UCSF. He also completed his training in hospital medicine at UCSF.

Rosenbluth joined the UCSF faculty in 2005 and was one of four doctors to receive the UCSF Exceptional Physician Award in 2006. He serves as associate director of the pediatric residency program and as director of quality and safety programs for the Office of Graduate Medical Education.

Education & training

Board certification

  • Pediatric Hospitalist, American Board of Pediatrics
  • Pediatrics, American Board of Pediatrics

Degree

  • MD, Cornell University at Ithaca

Academic Title

  • Health Sciences Clinical Professor

My expertise

  • Specialties
    • Pediatric Hospital Medicine

Locations

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

    For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.

    The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.